Measuring treatment response in malignant pleural mesothelioma using breathprinting technology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of electronic nose (E-Nose) technology to assess how patients with malignant pleural mesothelioma respond to standard treatment. Researchers will analyze changes in breathprints over time and compare these changes to standard imaging scans and blood biomarkers. The goal is to determine if E-Nose can provide a non-invasive method to monitor treatment efficacy in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 30-85 years
* No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
* Recent diagnosis of MPM
* Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Exclusion Criteria:

* Aged \<30 or \>85 years at the first outpatient visit
* History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Where it's running

• Memorial Sloan Kettering Basking Ridge (Consent Only)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Consent Only)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Consent Only )
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Consent Only)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Gaetano Rocco, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Gaetano Rocco, MD
• Email: roccog@mskcc.org
• Phone: 212-639-3478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining a PD-L1 inhibitor and dendritic cell vaccination with chemotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines a PD-L1 blocker and a special vaccine with chemotherapy to see if it helps people with a type of lung cancer called malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 University Hospital, Antwerp · Edegem, Antwerp and 2 other locations · NCT05765084

• Proton therapy for treating malignant pleural mesothelioma

  This study is testing if proton therapy can help people with malignant pleural mesothelioma live longer and feel better compared to standard care.

  Recruiting at 24 sites University College, London · Eastbourne, East Sussex and 24 other locations · NCT05655078

• Innovative treatment combining photodynamic therapy and immunotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines light therapy and immune therapy to see if it can help patients with advanced malignant pleural mesothelioma who haven't responded well to chemotherapy.

  Recruiting Phase 2 University Hospital, Lille · Lille · NCT04400539

• APG-2449 for advanced solid tumors

  This study is testing a new oral medication called APG-2449 to see how well it works and what the safe dosage is for people with advanced solid tumors like non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 8 other locations · NCT03917043

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.